Phase 2CompletedINTERVENTIONAL
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
ClinicalTrials.gov · NCT01556594 · Registry updated: 2019-09-23
- Condition / research focus
- Hypoglycemia
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- Canada
- Registry dates and results
- Start: 2012-03. Completion: 2012-07 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Nasal Glucagon 1 mg (drug) — also listed as: Dry Powder Nasal Glucagon, AMG504-1, LY900018
- Nasal Glucagon 2 mg (drug) — also listed as: Dry Powder Nasal Glucagon, AMG504-1, LY900018
- SC Glucagon (drug) — also listed as: Glucagon, Glucagon for injection (rDNA origin)
- Nasal Glucagon 3 mg (drug) — also listed as: Dry Powder Nasal Glucagon, AMG504-1, LY900018
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Algorithme Pharma
Montreal, Quebec, Canada
Site recruitment: Not reported